ERBB2 and colorectal carcinoma: As this assay is designed to detect DNA alterations, such as amplification in the blood, and not the absence or low level of protein expression represented by 0, and HER2 low CRC, which include 1 + and 2 + non amplified cases, the evaluation of HER2 by IHC remains relevant.